Ipsen S.A. (OTCMKTS:IPSEY) Short Interest Up 400.0% in February

Ipsen S.A. (OTCMKTS:IPSEY) was the recipient of a large increase in short interest in the month of February. As of February 15th, there was short interest totalling 500 shares, an increase of 400.0% from the January 31st total of 100 shares. Based on an average trading volume of 1,200 shares, the short-interest ratio is presently 0.4 days.

Ipsen Stock Performance

Shares of IPSEY stock traded up $0.82 during mid-day trading on Friday, hitting $28.88. The company’s stock had a trading volume of 759 shares, compared to its average volume of 812. Ipsen has a 52 week low of $27.09 and a 52 week high of $34.06. The company’s fifty day simple moving average is $29.97 and its 200-day simple moving average is $29.91.

Ipsen Company Profile

Ipsen SA operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.